Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer

Oncologist

Volumn 21, Issue 8, 2016, Pages 988-994

  Moretto, Roberto ^a,b   Cremolini, Chiara ^a,b   Rossini, Daniele ^a,b   Pietrantonio, Filippo ^c   Battaglin, Francesca ^d   Amennitto, Alessi ^c   Bergamo, Francesca ^d   Loupakis, Fotios ^a,b   Marmorino, Federica ^a,b   Berenato, Rosa ^c   Angelamarsico, Valentina ^d   Caporale, Marta ^c   Antoniotti, Carlotta ^a,b   Masi, Gianluca ^a,b   Salvatore, Lisa ^a,b   Borelli, Beatrice ^a,b   Fontanini, Gabriella ^b   Lonardi, Sara ^d   De Braud, Filippo ^c   Falconea, Alfredo ^a,b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Anti EGFR monoclonal antibodies; Left sided tumor; Metastatic colorectal cancer; Right sided tumor

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN; REGORAFENIB; TIPIRACIL PLUS TRIFLURIDINE; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; DISEASE CONTROL; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTATIC COLORECTAL CANCER; MIDDLE AGED; ONCOGENE; ONCOGENE BRAF; ONCOGENE RAS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER OF UNKNOWN PRIMARY SITE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84981557065     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0084     Document Type: Article

References (18)

1. Bufill JA. Colorectal cancer: Evidence for distinct genetic categories basedonproximal or distaltumor location. Ann Intern Med 1990;113:779-788
2. Distler P, Holt PR. Are right-and left-sided colon neoplasms distinct tumors? Dig Dis 1997; 15:302-311
3. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101:403-408
4. Tran B, Kopetz S, Tie J et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117: 4623-4632
5. Hutchins G, Southward K, Handley K et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29: 1261-1270
6. Missiaglia E, Jacobs B, D’Ario G et al. Distal and proximal colon cancers differ in terms ofmolecular, pathological, and clinical features. Ann Oncol 2014; 25:1995-2001
7. Sunakawa Y, Ichikawa W, Tsuji A et al. Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatinbased chemotherapy: A subgroup analysis of the JACCRO CC-05/06. J Clin Oncol 2016;34(suppl 4S): 613a
8. Matos I, Ortiz C, Elez E et al. Prognostic impact of primary tumor site location in metastatic colorectal cancer (mCRC). J Clin Oncol 2016;34(suppl 4S): 578a
9. Loupakis F, Yang D, Yau L et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107:107
10. von Einem JC, Heinemann V, von Weikersthal LF et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: An analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014;140:1607-1614
11. Heinemann V, Modest DP, von Weikerstahl LF et al. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 2014;32(suppl 5S):3600a
12. Brulé SY, Jonker DJ, Karapetis CS et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015;51: 1405-1414
13. Sorich MJ, Wiese MD, Rowland A et al. Extended RASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann Oncol 2015;26:13-21
14. Pietrantonio F, Petrelli F, Coinu A et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximaband panitumumab: A meta-analysis. Eur J Cancer 2015; 51:587-594
15. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-1356
16. Grimminger PP, Shi M, Barrett C et al. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer inCONFIRM-1 and-2 clinical trials. Pharmacogenomics J 2012;12: 404-411
17. Jacobs B, De Roock W, Piessevaux H et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-5074
18. Scartozzi M, Bearzi I, Mandolesi A et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer 2011;104: 1786-1790.